FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Thomas Prisinzano

Research Profile

Chemicals & Drugs

Living Beings

Co-author Network

Publications

TOP 3
Thomas E Prisinzano
Neoclerodanes as atypical opioid receptor ligands.
Barbara N Timmermann; Thomas E Prisinzano
Special issue in honor of Lester A. Mitscher.
Katherine A MacLean; Thomas E Prisinzano; Chad J Reissig; Matthew W Johnson; Roland R Griffiths
Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Thomas Prisinzano (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Thomas E Prisinzano
Neoclerodanes as atypical opioid receptor ligands.
Journal of medicinal chemistry 2013;56(9):3435-43.
2013: Barbara N Timmermann; Thomas E Prisinzano
Special issue in honor of Lester A. Mitscher.
Journal of natural products 2013;76(3):303-4.
2013: Katherine A MacLean; Thomas E Prisinzano; Chad J Reissig; Matthew W Johnson; Roland R Griffiths
Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects.
Psychopharmacology 2013;226(2):381-92.
2013: Jade M Franklin; Thomas E Prisinzano; Tamara Vasiljevik; Gonzalo A Carrasco
Cannabinoid agonists increase the interaction between β-Arrestin 2 and ERK1/2 and upregulate β-Arrestin 2 and 5-HT(2A) receptors.
Pharmacological research : the official journal of the Italian Pharmacological Society 2013;68(1):46-58.
2012: Hefei Zhang; Thomas E Prisinzano; Maureen D Donovan
Permeation and metabolism of cocaine in the nasal mucosa.
European journal of drug metabolism and pharmacokinetics 2012;37(4):255-62.
2012: Blake P Moore; James W Noah; Thomas E Prisinzano; Lynn Rasmussen; Melinda I Sosa; Nichole A Tower; E Lucile White; Subramaniam Ananthan; Jeffrey Aubé; Dong Hoon Chung; Jennifer E Golden; Fuli Jia; Colleen B Jonsson; Clinton Maddox; Daljit S Matharu; William Severson
(S)-N-(2,5-Dimethylphenyl)-1-(quinoline-8-ylsulfonyl)pyrrolidine-2-carboxamide as a small molecule inhibitor probe for the study of respiratory syncytial virus infection.
Journal of medicinal chemistry 2012;55(20):8582-7.
2012: Claus Loland; Sonia Mazier; Maddalena Mereu; Oluyomi M Okunola; Thomas E Prisinzano; Lei Shi; Gianluigi Tanda; Jianjing Cao; Jonathan L Katz; Theresa A Kopajtic; Amy Hauck Newman
R-modafinil (armodafinil): a unique dopamine uptake inhibitor and potential medication for psychostimulant abuse.
Biological psychiatry 2012;72(5):405-13.
2012: Eduardo R Butelman; Michael Caspers; Mary Jeanne Kreek; Kimberly M Lovell; Thomas E Prisinzano
Behavioral effects and central nervous system levels of the broadly available κ-agonist hallucinogen salvinorin A are affected by P-glycoprotein modulation in vivo.
The Journal of pharmacology and experimental therapeutics 2012;341(3):802-8.
2012: Kimberly M Lovell; Anthony Lozama; Katherine M Prevatt-Smith; Juan J Araya; Eduardo R Butelman; Victor Warren Day; Christina M Dersch; Mary Jeanne Kreek; Richard B Rothman; Tamara Vasiljevik; Thomas E Prisinzano
Semisynthetic neoclerodanes as kappa opioid receptor probes.
Bioorganic & medicinal chemistry 2012;20(9):3100-10.
2012: Aashish S Morani; Thomas E Prisinzano; Susan Schenk; Bronwyn Maree Kivell
A single injection of a novel κ opioid receptor agonist salvinorin A attenuates the expression of cocaine-induced behavioral sensitization in rats.
Behavioural pharmacology 2012;23(2):162-70.
2012: Lisa K Brents; William E Fantegrossi; Anna Gallus-Zawada; Jeffery H Moran; Thomas E Prisinzano; Anna Radominska-Pandya; Tamara Vasiljevik; Paul L Prather
Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity.
Biochemical pharmacology 2012;83(7):952-61.
2012: Kenneth Lamb; Denise S Simpson; Kevin Tidgewell; Laura M Bohn; Thomas E Prisinzano
Antinociceptive effects of herkinorin, a MOP receptor agonist derived from salvinorin A in the formalin test in rats: new concepts in mu opioid receptor pharmacology: from a symposium on new concepts in mu-opioid pharmacology.
Drug and alcohol dependence 2012;121(3):181-8.
2011: Christopher W Cunningham; Richard B Rothman; Thomas E Prisinzano
Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A.
Pharmacological reviews 2011;63(2):316-47.
2011: Matthew W Johnson; Katherine A MacLean; Chad J Reissig; Thomas E Prisinzano; Roland R Griffiths
Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum.
Drug and alcohol dependence 2011;115(1-2):150-5.
2011: Anthony Lozama; Christopher W Cunningham; Michael J Caspers; Justin T Douglas; Christina M Dersch; Richard B Rothman; Thomas E Prisinzano
Opioid receptor probes derived from cycloaddition of the hallucinogen natural product salvinorin A.
Journal of natural products 2011;74(4):718-26.
2011: Kimberly M Lovell; Katherine M Prevatt-Smith; Anthony Lozama; Thomas E Prisinzano
Synthesis of neoclerodane diterpenes and their pharmacological effects.
Topics in current chemistry 2011;299():141-85.
2010: Jennifer L Newman; S Stevens Negus; Anthony Lozama; Thomas E Prisinzano; Nancy K Mello
Behavioral evaluation of modafinil and the abuse-related effects of cocaine in rhesus monkeys.
Experimental and clinical psychopharmacology 2010;18(5):395-408.
2010: Nyssa Drinkwater; Hoan Vu; Kimberly M Lovell; Kevin R Criscione; Brett M Collins; Thomas E Prisinzano; Sally-Ann Poulsen; Michael McLeish; Gary L Grunewald; Jennifer L Martin
Fragment-based screening by X-ray crystallography, MS and isothermal titration calorimetry to identify PNMT (phenylethanolamine N-methyltransferase) inhibitors.
The Biochemical journal 2010;431(1):51-61.
2010: Christopher W Cunningham; Archana Mukhopadhyay; Gerald H Lushington; Brian S J Blagg; Thomas E Prisinzano; Jeffrey P Krise
Uptake, distribution and diffusivity of reactive fluorophores in cells: implications toward target identification.
Molecular pharmaceutics 2010;7(4):1301-10.
2010: Bronwyn M Kivell; Thomas E Prisinzano
Kappa opioids and the modulation of pain.
Psychopharmacology 2010;210(2):109-19.
2010: Eduardo R Butelman; Szymon Rus; Thomas E Prisinzano; Mary Jeanne Kreek
The discriminative effects of the kappa-opioid hallucinogen salvinorin A in nonhuman primates: dissociation from classic hallucinogen effects.
Psychopharmacology 2010;210(2):253-62.
2010: Elliott J Sally; Heng Xu; Christina M Dersch; Ling-Wei Hsin; Li-Te Chang; Thomas E Prisinzano; Denise S Simpson; Denise Giuvelis; Kenner C Rice; Arthur E Jacobson; Kejun Cheng; Edward J Bilsky; Richard B Rothman
Identification of a novel "almost neutral" micro-opioid receptor antagonist in CHO cells expressing the cloned human mu-opioid receptor.
Synapse (New York, N.Y.) 2010;64(4):280-8.
2010: Katherine M Prevatt-Smith; Thomas E Prisinzano
New therapeutic potential for psychoactive natural products.
Natural product reports 2010;27(1):23-31.
2009: Aashish S Morani; Bronwyn Kivell; Thomas E Prisinzano; Susan Schenk
Effect of kappa-opioid receptor agonists U69593, U50488H, spiradoline and salvinorin A on cocaine-induced drug-seeking in rats.
Pharmacology, biochemistry, and behavior 2009;94(2):244-9.
2009: Denise S Simpson; Kimberly M Lovell; Anthony Lozama; Nina Han; Victor Warren Day; Christina M Dersch; Richard B Rothman; Thomas E Prisinzano
Synthetic studies of neoclerodane diterpenes from Salvia divinorum: role of the furan in affinity for opioid receptors.
Organic & biomolecular chemistry 2009;7(18):3748-56.
2009: Anthony Lozama; Thomas E Prisinzano
Chemical methods for the synthesis and modification of neoclerodane diterpenes.
Bioorganic & medicinal chemistry letters 2009;19(18):5490-5.
2009: Zeynep S Teksin; Insong J Lee; Noble N Nemieboka; Ahmed A Othman; Vijay V Upreti; Hazem E Hassan; Shariq S Syed; Thomas E Prisinzano; Natalie D. Eddington
Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V 2009;72(2):471-7.
2009: Kimberly M Lovell; Denise S Simpson; Christopher W Cunningham; Thomas E Prisinzano
Utilizing nature as a source of new probes for opioid pharmacology.
Future medicinal chemistry 2009;1(2):285-301.
2009: Dorota Zolkowska; Raka Jain; Richard B Rothman; John S Partilla; Bryan L Roth; Vincent Setola; Thomas E Prisinzano; Michael H Baumann
Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil.
The Journal of pharmacology and experimental therapeutics 2009;329(2):738-46.
2009: Thomas E Prisinzano
Natural products as tools for neuroscience: discovery and development of novel agents to treat drug abuse.
Journal of natural products 2009;72(3):581-7.
2009: Eduardo R Butelman; Thomas E Prisinzano; Haiteng Deng; Szymon Rus; Mary Jeanne Kreek
Unconditioned behavioral effects of the powerful kappa-opioid hallucinogen salvinorin A in nonhuman primates: fast onset and entry into cerebrospinal fluid.
The Journal of pharmacology and experimental therapeutics 2009;328(2):588-97.
2009: Brian D Fink; Yunxia O'Malley; Brian L Dake; Nicolette C Ross; Thomas E Prisinzano; William I Sivitz
Mitochondrial targeted coenzyme Q, superoxide, and fuel selectivity in endothelial cells.
PloS one 2009;4(1):e4250.
2008: Gary E L Brandt; Matthew D Schmidt; Thomas E Prisinzano; Brian S J Blagg
Gedunin, a novel hsp90 inhibitor: semisynthesis of derivatives and preliminary structure-activity relationships.
Journal of medicinal chemistry 2008;51(20):6495-502.
2008: Eduardo R Butelman; Szymon Rus; Denise S Simpson; Angela Wolf; Thomas E Prisinzano; Mary Jeanne Kreek
The effects of herkinorin, the first mu-selective ligand from a salvinorin A-derived scaffold, in a neuroendocrine biomarker assay in nonhuman primates.
The Journal of pharmacology and experimental therapeutics 2008;327(1):154-60.
2008: Heng Xu; Xiaoying Wang; John S Partilla; Kristen Bishop-Mathis; tova benaderet; Christina M Dersch; Denise S Simpson; Thomas E Prisinzano; Richard B Rothman
Differential effects of opioid agonists on G protein expression in CHO cells expressing cloned human opioid receptors.
Brain research bulletin 2008;77(1):49-54.
2008: Thomas E Prisinzano; Richard B Rothman
Salvinorin A analogs as probes in opioid pharmacology.
Chemical reviews 2008;108(5):1732-43.
2008: Kevin Tidgewell; Chad E Groer; Wayne W Harding; Anthony Lozama; Matthew Schmidt; Alfred Marquam; Jessica Hiemstra; John S Partilla; Christina M Dersch; Richard B Rothman; Laura M Bohn; Thomas E Prisinzano
Herkinorin analogues with differential beta-arrestin-2 interactions.
Journal of medicinal chemistry 2008;51(8):2421-31.
2008: Richard B Rothman; Michael H Baumann; Thomas E Prisinzano; Amy Hauck Newman
Dopamine transport inhibitors based on GBR12909 and benztropine as potential medications to treat cocaine addiction.
Biochemical pharmacology 2008;75(1):2-16.
2007: Kenneth G Holden; Kevin Tidgewell; Alfred Marquam; Richard B Rothman; Hernán Navarro; Thomas E Prisinzano
Synthetic studies of neoclerodane diterpenes from Salvia divinorum: exploration of the 1-position.
Bioorganic & medicinal chemistry letters 2007;17(22):6111-5.
2007: Peter L Katavic; Kenneth Lamb; Hernan Navarro; Thomas E Prisinzano
Flavonoids as opioid receptor ligands: identification and preliminary structure-activity relationships.
Journal of natural products 2007;70(8):1278-82.
2007: Denise S Simpson; Peter L Katavic; Anthony Lozama; Wayne W Harding; Damon Parrish; Jeffrey Deschamps; Christina M Dersch; John S Partilla; Richard B Rothman; Hernan Navarro; Thomas E Prisinzano
Synthetic studies of neoclerodane diterpenes from Salvia divinorum: preparation and opioid receptor activity of salvinicin analogues.
Journal of medicinal chemistry 2007;50(15):3596-603.
2007: Heng Xu; John S Partilla; Xiaoying Wang; John M Rutherford; Kevin Tidgewell; Thomas E Prisinzano; Laura M Bohn; Richard B Rothman
A comparison of noninternalizing (herkinorin) and internalizing (DAMGO) mu-opioid agonists on cellular markers related to opioid tolerance and dependence.
Synapse (New York, N.Y.) 2007;61(3):166-75.
2007: C E Groer; Kevin Tidgewell; R A Moyer; Wayne W Harding; Richard B Rothman; Thomas E Prisinzano; Laura M Bohn
An opioid agonist that does not induce mu-opioid receptor--arrestin interactions or receptor internalization.
Molecular pharmacology 2007;71(2):549-57.
2007: Richard B Rothman; Daniel L Murphy; Heng Xu; Jonathan A Godin; Christina M Dersch; John S Partilla; Kevin Tidgewell; Matthew Schmidt; Thomas E Prisinzano
Salvinorin A: allosteric interactions at the mu-opioid receptor.
The Journal of pharmacology and experimental therapeutics 2007;320(2):801-10.
2007: Kathleen M Gilbert; Terrence L Boos; Christina M Dersch; Elisabeth Greiner; Arthur E Jacobson; David Lewis; Dorota Matecka; Thomas E Prisinzano; Ying Zhang; Richard B Rothman; Kenner C Rice; Carol A Venanzi
DAT/SERT selectivity of flexible GBR 12909 analogs modeled using 3D-QSAR methods.
Bioorganic & medicinal chemistry 2007;15(2):1146-59.
2007: Eduardo R Butelman; Marek Mandau; Kevin Tidgewell; Thomas E Prisinzano; Vadim Yuferov; Mary Jeanne Kreek
Effects of salvinorin A, a kappa-opioid hallucinogen, on a neuroendocrine biomarker assay in nonhuman primates with high kappa-receptor homology to humans.
The Journal of pharmacology and experimental therapeutics 2007;320(1):300-6.
2006: Yunxia Q O'Malley; Brian D Fink; Nicolette C Ross; Thomas E Prisinzano; William I Sivitz
Reactive oxygen and targeted antioxidant administration in endothelial cell mitochondria.
The Journal of biological chemistry 2006;281(52):39766-75.
2006: Piyush M Vyas; Sanjoy Roychowdhury; Farah D Khan; Thomas E Prisinzano; Jatinder Lamba; Erin G Schuetz; Joyce Blaisdell; Joyce A Goldstein; Kimber L Munson; Ronald Hines; Craig K Svensson
Enzyme-mediated protein haptenation of dapsone and sulfamethoxazole in human keratinocytes: I. Expression and role of cytochromes P450.
The Journal of pharmacology and experimental therapeutics 2006;319(1):488-96.
2006: Nagendra V Chemuturi; Jon E Haraldsson; Thomas E Prisinzano; Maureen Donovan
Role of dopamine transporter (DAT) in dopamine transport across the nasal mucosa.
Life sciences 2006;79(14):1391-8.
2006: Wayne W Harding; Matthew Schmidt; Kevin Tidgewell; Pavitra Kannan; Kenneth G Holden; Christina M Dersch; Richard B Rothman; Thomas E Prisinzano
Synthetic studies of neoclerodane diterpenes from Salvia divinorum: selective modification of the furan ring.
Bioorganic & medicinal chemistry letters 2006;16(12):3170-4.
2006: Kevin Tidgewell; Wayne W Harding; Anthony Lozama; Howard Cobb; Kushal Shah; Pavitra Kannan; Christina M Dersch; Damon Parrish; Jeffrey Deschamps; Richard B Rothman; Thomas E Prisinzano
Synthesis of salvinorin A analogues as opioid receptor probes.
Journal of natural products 2006;69(6):914-8.
2006: Terrence L Boos; Elisabeth Greiner; W Jason Calhoun; Thomas E Prisinzano; Barbara Nightingale; Christina M Dersch; Richard B Rothman; Arthur E Jacobson; Kenner C Rice
Structure-activity relationships of substituted N-benzyl piperidines in the GBR series: Synthesis of 4-(2-(bis(4-fluorophenyl)methoxy)ethyl)-1-(2-trifluoromethylbenzyl)piperidine, an allosteric modulator of the serotonin transporter.
Bioorganic & medicinal chemistry 2006;14(11):3967-73.
2006: Elisabeth Greiner; Terrence L Boos; Thomas E Prisinzano; Maria G De Martino; Brian Zeglis; Christina M Dersch; Jamila Marcus; John S Partilla; Richard B Rothman; Arthur E Jacobson; Kenner C Rice
Design and synthesis of promiscuous high-affinity monoamine transporter ligands: unraveling transporter selectivity.
Journal of medicinal chemistry 2006;49(5):1766-72.
2006: Wayne W Harding; Matthew Schmidt; Kevin Tidgewell; Pavitra Kannan; Kenneth G Holden; Brian Gilmour; Hernan Navarro; Richard B Rothman; Thomas E Prisinzano
Synthetic studies of neoclerodane diterpenes from Salvia divinorum: semisynthesis of salvinicins A and B and other chemical transformations of salvinorin A.
Journal of natural products 2006;69(1):107-12.
2005: Thomas E Prisinzano
Psychopharmacology of the hallucinogenic sage Salvia divinorum.
Life sciences 2005;78(5):527-31.
2005: Matthew D Schmidt; Mark S Schmidt; Eduardo R Butelman; Wayne W Harding; Kevin Tidgewell; Daryl J Murry; Mary Jeanne Kreek; Thomas E Prisinzano
Pharmacokinetics of the plant-derived kappa-opioid hallucinogen salvinorin A in nonhuman primates.
Synapse (New York, N.Y.) 2005;58(3):208-10.
2005: Agnieszka Sulima; Thomas E Prisinzano; Thomas Spande; Jeffrey Deschamps; Noel Whittaker; Zeev Hochberg; Arthur E Jacobson; Kenner C Rice
A concise method for the preparation of deuterium-labeled cortisone: synthesis of [6,7-2H]cortisone.
Steroids 2005;70(11):763-9.
2005: Wayne W Harding; Kevin Tidgewell; Nathan Byrd; Howard Cobb; Christina M Dersch; Eduardo R Butelman; Richard B Rothman; Thomas E Prisinzano
Neoclerodane diterpenes as a novel scaffold for mu opioid receptor ligands.
Journal of medicinal chemistry 2005;48(15):4765-71.
2005: Wayne W Harding; Kevin Tidgewell; Matthew Schmidt; Kushal Shah; Christina M Dersch; John Snyder; Damon Parrish; Jeffrey Deschamps; Richard B Rothman; Thomas E Prisinzano
Salvinicins A and B, new neoclerodane diterpenes from Salvia divinorum.
Organic letters 2005;7(14):3017-20.
2005: Mark S Schmidt; Thomas E Prisinzano; Kevin Tidgewell; Wayne W Harding; Eduardo R Butelman; Mary Jeanne Kreek; Daryl J Murry
Determination of Salvinorin A in body fluids by high performance liquid chromatography-atmospheric pressure chemical ionization.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2005;818(2):221-5.
2005: Thomas E Prisinzano; Kevin Tidgewell; Wayne W Harding
Kappa opioids as potential treatments for stimulant dependence.
The AAPS journal 2005;7(3):E592-9.
2004: Kevin Tidgewell; Wayne W Harding; Mark Schmidt; Kenneth G Holden; Daryl J Murry; Thomas E Prisinzano
A facile method for the preparation of deuterium labeled salvinorin A: synthesis of [2,2,2-2H3]-salvinorin A.
Bioorganic & medicinal chemistry letters 2004;14(20):5099-102.
2004: Thomas E Prisinzano; Malgorzata Dukat; Ho Law; Abdelmalik Slassi; Neil MacLean; Inés DeLannoy; Richard A Glennon
2-(Anilino)imidazolines and 2-(benzyl)imidazoline derivatives as h5-HT1D serotonin receptor ligands.
Bioorganic & medicinal chemistry letters 2004;14(18):4697-9.
2003: Richard B Rothman; Subramaniam Jayanthi; Xiaoying Wang; Christina M Dersch; Jean Lud Cadet; Thomas E Prisinzano; Kenner C Rice; Michael H Baumann
High-dose fenfluramine administration decreases serotonin transporter binding, but not serotonin transporter protein levels, in rat forebrain.
Synapse (New York, N.Y.) 2003;50(3):233-9.
2003: Elisabeth Greiner; Thomas E Prisinzano; Edward M Johnson; Christina M Dersch; Jamila Marcus; John S Partilla; Richard B Rothman; Arthur E Jacobson; Kenner C Rice
Structure-activity relationship studies of highly selective inhibitors of the dopamine transporter: N-benzylpiperidine analogues of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine.
Journal of medicinal chemistry 2003;46(8):1465-9.
2003: David Lewis; Ying Zhang; Thomas E Prisinzano; Christina M Dersch; Richard B Rothman; Arthur E Jacobson; Kenner C Rice
Further exploration of 1-[2-[Bis-(4-fluorophenyl)methoxy]ethyl]piperazine (GBR 12909): role of N-aromatic, N-heteroaromatic, and 3-oxygenated N-phenylpropyl substituents on affinity for the dopamine and serotonin transporter.
Bioorganic & medicinal chemistry letters 2003;13(7):1385-9.
2003: Ling-Wei Hsin; Thomas E Prisinzano; Chavon R Wilkerson; Christina M Dersch; Robert Horel; Arthur E Jacobson; Richard B Rothman; Kenner C Rice
Synthesis and dopamine transporter affinity of chiral 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(2-hydroxypropyl)piperazines as potential cocaine abuse therapeutic agents.
Bioorganic & medicinal chemistry letters 2003;13(3):553-6.
2002: Thomas E Prisinzano; Elisabeth Greiner; Edward M Johnson; Christina M Dersch; Jamila Marcus; John S Partilla; Richard B Rothman; Arthur E Jacobson; Kenner C Rice
Piperidine analogues of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR 12909): high affinity ligands for the dopamine transporter.
Journal of medicinal chemistry 2002;45(19):4371-4.
2002: Han Yu; Thomas E Prisinzano; Christina M Dersch; Jamila Marcus; Richard B Rothman; Arthur E Jacobson; Kenner C Rice
Synthesis and biological activity of 8beta-substituted hydrocodone indole and hydromorphone indole derivatives.
Bioorganic & medicinal chemistry letters 2002;12(2):165-8.
2001: Thomas E Prisinzano; Ho Law; Malgorzata Dukat; Abdelmalik Slassi; Neil MacLean; Lidia Demchyshyn; Richard A Glennon
Imidazoline-modified benzylimidazolines as h5-HT(1D/1B) serotonergic ligands.
Bioorganic & medicinal chemistry 2001;9(3):613-9.
1998: Ho Law; Malgorzata Dukat; Milt Teitler; DK Lee; L Mazzocco; Rajender K Kamboj; V Rampersad; Thomas E Prisinzano; Richard A Glennon
Benzylimidazolines as h5-HT1B/1D serotonin receptor ligands: a structure-affinity investigation.
Journal of medicinal chemistry 1998;41(13):2243-51.